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To explore the role of the kallikrein–kinin system in relation to
ischemia/reperfusion injury in the kidney, we generated mice lacking
both the bradykinin B1 and B2 receptor genes (B1RB2R-null, Bdkrb1/
/Bdkrb2/) by deleting the genomic region encoding the two
receptors. In 4-month-old mice, blood pressures were not significantly
different among B1RB2R-null, B2R-null (Bdkrb2/), and WT mice.
After 30 min of bilateral renal artery occlusion and 24 h of reperfusion,
mortality rates, renal histological and functional changes, 8-hydroxy-
2-deoxyguanosine levels in total DNA, mtDNA deletions, and the
number of TUNEL-positive cells in the kidneys increased progressively
in the following order (from lowest to highest): WT, B2R-null, and
B1RB2R-null mice. Increases in mRNA levels of TGF-1, connective
tissue growth factor, and endothelin-1 after ischemia/reperfusion
injury were also exaggerated in the same order (from lowest to
highest): WT, B2R-null, and B1RB2R-null. Thus, both the B1 and B2
bradykinin receptors play an important role in reducing DNA damage,
apoptosis, morphological and functional kidney changes, and mor-
tality during renal ischemia/reperfusion injury.
hypoxia  mitochondria  oxidative stress
Ischemic tissue injuries, including stroke, myocardial infarction,and ischemic acute renal failure, are devastating complications
in patients with hypertension, diabetes, atherosclerosis, and
senescence. In organ transplantation, damage to allografts dur-
ing any ischemic period before the transplant markedly influ-
ences short-term and long-term graft function and outcome (1).
Furthermore, although reoxygenation after ischemia is essential
for cell survival, damage also develops during the reperfusion
period. Previous studies have shown that acute ATP depletion,
intracellular Ca2 accumulation, and increased generation of
reactive oxygen species by mitochondria all play important roles
in the pathogenesis of ischemia/reperfusion (I/R) injury (2).
Angiotensin-I-converting enzyme (ACE) inhibitors (ACEIs) re-
duce not only chronic cardiovascular remodeling after ischemia but
also acute tissue injury caused by I/R in the heart (3), lung (4), liver
(5), and kidneys (6, 7). Several observations indicate that the
beneficial effects of ACEIs in the acute phase are mainly due to
activation of the bradykinin nitric oxide (NO) cascade as a result of
inhibition of the inactivation of bradykinin, rather than due to
suppression of angiotensin II formation. Thus, ACEIs are much
more effective than angiotensin type I receptor antagonists in
protecting against I/R (8–10), and bradykinin B2 receptor (B2R)
antagonists and NO synthase blockers markedly attenuate the
protective effects of ACEIs (8, 9, 11).
Bradykinin and lysyl–bradykinin (kallidin) are generated from
kininogens by the kallikreins and some other serine proteases.
ACE, which is a carboxydipeptidase, inactivates both peptides by
removing two amino acids from their carboxyl termini. In mam-
mals, at least two receptors have been identified: the bradykinin B1
receptor (B1R) and the B2R. Expression of the B2R is constitutive
and high in most tissues, except liver and spleen (12). The B1R is
expressed at low levels in normal tissues but is induced after tissue
injury or after animals are treated with endotoxins or cytokines
(13). It has also been shown that expression of the B1R is markedly
induced when B2Rs are absent (14, 15). Both the B1R and B2R are
coupled with the Gq protein (the heterotrimeric G protein with
q subunit composition) (13), and their stimulation activates
endothelial NO synthase in the vascular endothelium (16–19).
In contrast to the consensus that ACEIs have beneficial effects
on I/R injury, previous studies have produced conflicting results
concerning the effect on I/R injury in different organs of stimulating
the two bradykinin receptors, B1R and B2R (20–22). In addition,
several studies have suggested that agonism of the B1R may have
opposite effects from agonism of the B2R on the severity of I/R
injury (23). Although expression of the B1R is much less than that
of B2R in the kidney and heart of WT mice, it is markedly induced
in B2R-null mice (14, 15), and expression of both receptors
increases in I/R injury (24). However, whether they act synergisti-
cally or antagonistically and whether or not the kallikrein–kinin
system has net protective effects in I/R injuries remain unanswered
questions. To answer these questions, we have generated mice
lacking both the B1R and B2R for comparison with WT mice and
with mice lacking the B2R only.
Because the genomic loci for the B1R and the B2R are close (11.0
kb), mice lacking both the B1R and B2R cannot be obtained
practically by simply crossbreeding mice lacking B1Rs and mice
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Fig. 1. Generation of B1RB2R-null mice lacking both B1R and B2R (Bdkrb1/
/Bdkrb2/). The top line indicates the target locus in ES cells from C57BL/6J
mice. RI, EcoRI site. The middle line indicates the targeting vector, including
the neomycin phosphotransferase gene (Neo) and thymidine kinase (TK)
genes. Bold lines indicate mouse genomic DNA sequences. The bottom line
indicates the resulting locus after homologous recombination. Both of the
receptor genes are now disrupted. Coding and noncoding exons of the
receptor genes are shown as black and white bars, respectively, and are
numbered. The location of the primers and probe used to identify recombi-
nants are shown as arrows (F and R) and a bar (probe).
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lacking B2Rs. To generate mice lacking both receptor genes
(B1RB2R-null, Bdkrb1//Bdkrb2/) we therefore deleted the
genomic region coding the two receptors, because no coding genes
are predicted to be between the B1R and B2R (Fig. 1). Here we
show that mice deficient in both receptors are extremely vulnerable
to renal I/R injury. Furthermore, because the order of the severity
of the injurious phenotypes increases progressively from WT to
B2R-null to B1RB2R-null, we conclude that the both the receptors
are important in reducing oxidative stress and protecting kidney
tissue from I/R injury.
Results
Three groups of mice were studied: homozygotes lacking both the
B1R and B2R (B1RB2R-null, Bdkrb1//Bdkrb2/), homozygotes
lacking B2Rs only (B2R-null, Bdkrb2/), and WT. Systolic blood
pressures, measured at 4 months age with a tail-cuff method before
carrying out the I/R, were not significantly different among the
three groups [WT, 108.7  1.5 mmHg (1 mmHg  133 Pa) (n 
15); B2R-null, 109.6  2.0 mmHg (n  14); B1RB2R-null, 110.7 
1.6 mmHg (n  17)]. Kidney function was also not significantly
different among the three groups of mice at 4 months of age, as
determined by plasma urea nitrogen and creatinine (data not
shown). However, fasting plasma levels of nitrite/nitrate, the ter-
minal metabolites of NO, decreased significantly in the three groups
of mice in the following order (from highest to lowest decrease):
WT, B2R-null, B1RB2R-null mice; this suggested the importance
of both the B1R and B2R in total NO production (Fig. 2).
Twenty-four hours after the renal I/R procedure, the mortality
rate was notably greater in B1RB2R-null (8 of 13) than in B2R-null
(1 of 8) and WT (0 of 10) mice (P  0.01 vs. WT, P  0.05 vs.
B2R-null; Fisher’s exact test), although no mortality was observed
in B1RB2R-null (0 of 10), B2R-null (0 of 7), or WT (0 of 5) mice
in sham-operated groups. In the surviving animals subjected to I/R,
plasma levels of urea nitrogen and creatinine in the B1RB2R-null
mice were higher than in B2R-null mice, which were higher than in
WT mice (Fig. 3), although there was no significant difference in
the urea nitrogen and creatinine levels among the sham-operated
groups of the three genotypes. The severity of histological changes
in renal proximal tubules were in the same order (from highest to
lowest): B1RB2R-null, B2R-null, WT mice (Fig. 4).
Oxidative stress, DNA damage, and apoptosis have all been
suggested to play a causative role in the functional and morpho-
logical changes accompanying I/R injury (2, 25). In agreement with
this suggestion, we found the levels of 8-hydroxy-2-deoxyguanosine
(8-OHdG), which is considered to be an index of oxidative DNA
modification (26), in total DNA of the kidney to be in the following
order (from highest to lowest): B1RB2R-null, B2R-null, WT mice
Fig. 2. Plasma levels of nitrite/nitrate in WT, B2R-null (Bdkrb2/), and
B1RB2R-null mice. *, P  0.01 vs. WT; †, P  0.01 vs. B2R-null. The data are
means  standard errors, with the numbers of animals shown in black digits.
Fig. 3. Plasma levels of urea nitrogen (A) and creatinine (B) as indices of renal
excretory function in WT, B2R-null, and B1RB2R-null mice. White and black
columns indicate sham-operated and ischemia groups, respectively. *, P  0.05
vs. the sham-operated group of the same genotype; †, P  0.05 vs. WT; ‡, P 
0.05 vs. B2R-null. The data are means  standard errors; the numbers of
animals are shown in white or black digits.
Fig. 4. Histological changes in the postischemic kidneys of WT, B2R-null, and
B1RB2R-null mice. (A) Periodic acid Schiff’s staining. Shown are stainings for
WT (Upper Left), B2R-null (Upper Right), and B1RB2R-null (Lower) mice. (Scale
bar, 100 m.) (B) Semiquantitative scoring for histological changes in the
proximal tubule according to the criteria of Jablonski et al. (56). The sham-
operated mice all a score of zero. The black columns show the scores of the
ischemia groups. †, P  0.05 vs. WT; ‡, P  0.05 vs. B2R-null. The data are
means  standard errors, with the numbers of animals shown in white digits.











(Fig. 5A). The proportion of the D-17 deletion mutant in mtDNA,
which increases with age (27) and diabetes (28) and has been shown
to be an indicator of mtDNA damage, was also higher in the kidney
subjected to the I/R injury in the same orders (from highest to
lowest): B1RB2R-null, B2R-null, and WT (Fig. 5B). The number
of apoptotic cells detected by TUNEL assay was likewise higher in
B1RB2R-null mice than in B2R-null, which was higher than in WT
mice (Fig. 6).
We next studied the mRNA levels of several I/R injury-related
genes with quantitative RT-PCR. The levels of B1R mRNA were
markedly increased in B2R-null mice, as previously shown, and
this enhanced expression in B2R-null mice was increased further
by I/R injury (Fig. 7A). Likewise, the levels of B2R mRNA were
increased by I/R injury (Fig. 7B). These findings indicate that I/R
injury increases the expression of both the B1R and the B2R.
We measured the mRNA levels of two components of the
renin–angiotensin system. As previously reported, the mRNA
levels of ACE and angiotensin II type 1A receptor (AT1AR) in
the kidney were markedly decreased in I/R injury. The expres-
sion of ACE and AT1AR was less in B1RB2R-null mice than in
B2R-null mice and less in B2R-null than in WT (Fig. 7 C and D).
We also studied gene expressions that are well known to be
increased in I/R injury. The mRNA levels of TGF-1 (29), con-
nective tissue growth factor (CTGF) (30), and endothelin (ET)-1
(31) were increased in I/R injury, and these increases were greater
in B1RB2R-null than in B2R-null mice and more in B2R-null than
in WT mice (Fig. 7 E–G). Expression of the relaxin family peptide
receptor 4, which has been suggested to serve as a bradykinin
receptor (32), was not significantly affected by the I/R procedure or
by the genotypes (not shown).
Discussion
The protective effect of ACEIs in cardiac I/R damage results largely
from inhibition of the enzymatic breakdown of endogenous bra-
dykinin and from the consequent enhancement of NO formation
(8, 9, 11, 33). Our present finding that the basal levels of fasting
plasma nitrite/nitrate are lower in B1RB2R-null than in B2R-null
and WT mice and a previous report showing that urinary nitrite/
nitrate excretion in B2R-null mice is lower than in WT mice (34)
are additional indicators that the kallikrein–kinin system is impor-
tant in basal NO production.
Recent studies have provided a likely explanation for this
protection: I/R injuries are associated with mitochondrial Ca2
overload resulting from a burst of reactive oxygen species, and the
combination of mitochondrial Ca2 overload and reactive oxy-
gen species triggers the opening of mitochondrial permeability-
transition pores and leads to cell apoptosis (35). This opening is
effectively suppressed by bradykinin (36). NO, a second mes-
senger of bradykinin receptors, reversibly suppresses mitochon-
drial oxidative metabolism (37–39) largely via inhibiting cyto-
chrome c oxidase in a cGMP-independent manner (40, 41).
In contrast to the consensus that ACEIs have beneficial effects
on I/R injury, previous reports are conflicting with respect to the
effects of pharmacological agents interacting with the bradykinin
receptors (20–22). In addition, several studies have suggested that
agonism of the B1R and B2R may have different effects on the
severity of I/R injury (21–23). In contrast, lack of the B1R (42) or
B2R (43) aggravates the I/R injury in the heart and brain of mice,
whereas adenovirus-mediated gene transfer of tissue kallikrein
protects against ischemic stroke in rats (44). Transgenic expression
of tissue kallikrein in mice attenuates ischemic cardiac damage (45),
whereas tissue kallikrein knockout in mice aggravates the damage
(24). In our current study, we show that I/R damage increases
progressively in the order WT, B2R-null, and B1RB2R-null, as
Fig. 5. DNA alterations in the postischemic kidneys of WT, B2R-null, and
B1RB2R-null mice. (A) The levels of 8-OHdG in total DNA of the kidney. (B)
Relative proportion of D-17 deletions (as a percentage of WT) in the mtDNA.
White and black columns indicate sham-operated and ischemia groups, re-
spectively. The data are means  standard errors, with the numbers of animals
shown in white or black digits. *, P  0.05 vs. the sham-operated group of the
same genotype; †, P  0.05 vs. WT; ‡, P  0.05 vs. B2R-null.
Fig. 6. TUNEL-positive cells in postischemic kidneys of WT, B2R-null, and
B1RB2R-null mice. (A) Representative photomicrographs of the renal cortex.
Shown are stainings for WT (Upper Left), B2R-null (Upper Right), and B1RB2R-
null (Lower) mice. (Scale bar, 100 m.) (B) Quantification of the number of
apoptotic cells in the renal cortex. The white and black columns indicate
sham-operated and ischemia groups, respectively. *, P  0.05 vs. the sham-
operated group of the same genotype; †, P  0.05 vs. WT. ‡, P  0.05 vs.
B2R-null. The data are means  standard errors, with the numbers of animals
shown in white or black digits.
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determined by morphological and functional changes to the kidney,
demonstrating clearly that both the B1R and B2R are important in
protecting the kidney from I/R injury.
Oxidative stress, DNA damage, and apoptotic changes have all
been implicated in I/R injury (25). We have previously reported
markedly increased levels of 8-OHdG in kidney DNA resulting
from the absence of B2Rs in animals with diabetes (28). In our
present study, we have clearly demonstrated that I/R increases
8-OHdG in kidney DNA in the following order (from lowest to
highest): WT, B2R-null, and B1RB2R-null. The most common
deletion mutant of mouse mtDNA (D-17), which increases with age
(27) and diabetes (28), was also markedly increased in the kidney
24 h after the I/R procedure. The increase in this mtDNA alteration
was enhanced progressively by absence of the B2R or of both the
B1R and B2R. We also found that tubular morphological changes
and the number of apoptotic cells after the I/R injury in the
B1RB2R-null mice was greater than in B2R-null mice, which was
greater than in WT.
Traditionally, the kallikrein–kinin system is viewed as a major
counteracting force to the renin–angiotensin system. In the current
study, we demonstrated that the expression of both ACE and
AT1AR is suppressed in I/R injury, as previously reported (46), and
this suppression is exaggerated in absence of bradykinin receptors.
The decrease in mRNA for ACE and AT1AR in I/R injury cannot
be explained merely by the loss of the proximal tubular cells, which
is the major site for ACE and AT1AR gene expression in the kidney
(47, 48), because, even in the WT mice subjected to I/R, where there
is little morphological change in proximal tubules, the expression of
ACE and AT1AR was substantially decreased. Given the well
documented ability of angiotensin II to stimulate reactive oxygen
species and to cause TGF-1 production, the down-regulation of
the renin–angiotensin system in I/R injury may be protective.
Previous studies have shown that TGF-1, CTGF, and ET-1
increase in hypoxic tissue damages (29–31), and that their expres-
sion increases with aging (49, 50) and diabetes (51–53). In the
present study, we found that these three genes were more expressed
in B1RB2R-null mice than B2R-null mice, and more expressed in
B2R-null mice than WT, suggesting that both B1R and B2R are
protective against renal cell damage in I/R injury. However, it is still
unclear whether increased expression of these genes in I/R injury
plays a primary/causative or secondary/protective role.
Our results show that the absence of the B1R and B2R, and to
a lesser extent, the absence of B2R alone, enhances a series of
changes including oxidative DNA damages, mtDNA deletions,
apoptosis, and the expression of TGF-1, CTGF, and ET-1, all of
which are common to other oxidative stress-related disorders.
Fig. 7. The expression of mRNA relative to -actin of B1R (A), B2R (B), ACE (C), AT1AR (D), TGF-1 (E), CTGF (F), and ET-1 (G), as determined by quantitative
RT-PCR and presented as percentages of sham-operated WT. The white and black columns indicate sham-operated and ischemia groups, respectively. The data
are means  standard errors, with the numbers of animals shown in white or black digits. *, P  0.05 vs. the sham-operated group of the same genotype; †, P 
0.05 vs. WT. ‡, P  0.05 vs. B2R-null.











Reduced plasma levels of end products of NO are associated with
the absence of B1R and B2R. Together, these data suggest that both
the B1R and B2R, presumably acting in part via NO, mitigate renal
I/R injury by blunting the marked increase in oxidative stress that
accompanies the I/R. Because ACEIs increase the level of brady-
kinin, our findings emphasize the importance of using ACEIs in
situations in which I/R injury is likely to occur. Pretransplant
treatment of the donor with ACEIs, as well as posttransplant
treatment of the recipient, merits consideration (5).
In summary, we have shown that the kallikrein–kinin system,
including both bradykinin B1R and B2R, is important in protecting
the kidney from damage caused by I/R. The B1RB2R-null mice that
we have generated should be useful for studying the role of
kallikrein–kinin system in other physiological and pathophysiolog-
ical conditions.
Methods
Animals. Mice having the null allele for the B2R, generated by
Borkowski et al. (54), were purchased from The Jackson Labora-
tory (Bar Harbor, ME) and bred in our mouse facility. The mice
were backcrossed to WT C57BL/6J at least six times. Mice lacking
both the B1R and B2R were generated in our laboratory and the
University of North Carolina Animal Models Core Facility. To do
this, we targeted C57BL/6J ES cells by using the scheme illustrated
in Fig. 1. The sequences of the primers for PCR screening of the
recombinants were as follows: forward, 5-ACGCGTCACCTTA-
ATATGCG-3 (in the Neo gene of the OS dupdel gene-targeting
vector; Open Biosystems, Huntsville, AL) (denoted as F in Fig. 1),
and reverse, 5-GTCCATTATCACCAAGGTGG-3 (in the Bd-
krb1 locus) (denoted as R in Fig. 1). Targeting was confirmed by a
Southern blot of genomic DNA digested with EcoRI by using a
434-bp KpnI–NcoI fragment (probe in Fig. 1) within the short
homology arm as the probe. The targeted ES cells were injected
into C57BL/6J blastocysts. Chimerism in the resulting mice was
assessed in their toe DNA by the amount of Neo gene relative to
-actin gene by real-time PCR with an Applied Biosystems 7700
Sequence Detection System (PerkinElmer, Boston, MA). Geno-
typing of subsequent progeny mice was performed by real-time
PCR with primers and probes for detection of the presence of the
Neo–Bdkrb1 junction [forward, 5-CTCGACATTGGGTG-
GAAACA-3 (in the Neo gene); reverse, 5-GGTGCTTCTGTCT-
TGTGACA-3 (in the Bdkrb1 locus); probe, 5-FAM-AGC-
CTCTCCACCCAGGCCTGG-TAMRA-3 (FAM and TAMRA
indicate 6-carboxyfluorescein and 5-6-carboxytetramethylrhodam-
ine, respectively)] and the absence of the third exon of Bdkrb2
(forward, 5-ATCTTGCAGGTGCTGAGGAA-3; reverse, 5-
AGCACAAAGAGCCCCAGGA-3; probe, 5-FAM-CAGCAC-
TAGCACGGTGGCCTTCCT-TAMRA-3). Systolic blood pres-
sure and pulse rate were measured with the tail-cuff method
described previously (55). All experiments performed were ap-
proved by the University of North Carolina Institutional Animal
Care and Use Committee.
Renal I/R. Mice were anesthetized with isoflurane (1.5%) inhalation,
and core body temperature was maintained at 37°C by using a
homeothermic blanket. After a midline laparotomy, heparin (10
units/kg i.m.) was injected. In I/R groups, renal arteries and veins
were bilaterally occluded by using microaneurysm clamps for 30
min. In sham-operated groups, renal arteries and veins were not
occluded, but the abdomen was kept open for 30 min. In I/R groups,
30 min after the occlusion, the incision was double-sutured after the
clamps were removed. Twenty-four hours after the removal of the
clamps, mice were killed and blood and renal tissues were collected.
Measurement of Biochemical Parameters. One month before the
ischemia experiment (after fasting for 4 h), and at the end of the
24-h reperfusion period, mice were anesthetized by using avertin
(2.5%; 0.1 mg/3 g i.p.), and blood was collected from the retroor-
bital sinus with heparinized glass pipettes. Samples were centri-
fuged (7,000  g for 5 min) to separate plasma. Plasma samples
were frozen and stored at 80°C before analyses for biochemical
parameters. Nitrite/nitrate in the plasma, partly derived from
endogenously produced NO, was measured with a nitric oxide
colorimetric assay kit, using the Griess method (Calbiochem, San
Diego, CA). Plasma urea nitrogen and creatinine concentrations
were measured by using the Vitros 250 chemistry system (Ortho-
Clinical Diagnostics, Raritan, NJ). 8-OHdG levels in DNase I-di-
gested kidney DNA (3 g) were determined with ELISA (Japan
Institute for Control of Aging/Nikken SEIL, Shizuoka, Japan).
Histological Evaluation. The left kidney was fixed with 4% (wt/vol)
paraformaldehyde. Renal tissue sections were stained with
periodic acid Schiff’s reagent with hematoxylin and examined by
optical microscopy. The histological changes in the proximal
tubule were semiquantified by using the criteria described by
Jablonski et al. (56).
Quantitative RT-PCR. Total RNA was extracted from whole kidney,
and the mRNAs for B1R, B2R, TGF-1, CTGF, ET-1, and relaxin
family peptide receptor 4 were assayed by quantitative RT-PCR, as
described previously (15, 28, 57). Expression of ET-1 and relaxin
family peptide receptor 4 was assayed with primers and probes for
the following: ET-1 (forward, 5-TGCCACCTGGACAT-
CATCTG-3; reverse, 5-ACGCTTGGACCTGGAAGAAC-3;
probe, 5-FAM-TCCCGAGCGCGTCGTACCGTATG-TAM-




Quantification of mtDNA Deletion Mutants. Occurrence of the most
common deletion mutant of mtDNA, D-17 (27), was assayed in
kidney DNA samples by using quantitative PCR with primers
flanking the deletion normalized by the amount of cytochrome b
gene, as previously described (28).
Fluorescence Microscopy. TUNEL assay was performed in the
paraformaldehyde-fixed kidney by using ApopTag Fluorescein In
Situ Apoptosis Detection Kit (Chemicon, Temecula, CA), as
previously described (28). The numbers of TUNEL-positive cells
were computationally counted (ImageJ version 1.33u; National
Institutes of Health).
Statistical Analysis. The data are expressed as means  standard
errors. To compare groups, we used two-factor ANOVA or the 2
test. Post hoc pairwise comparisons were by the Tukey–Kramer
honestly significant difference test or Fisher’s exact test (JMP
version 5.1.2; SAS Institute Inc., Cary, NC).
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